The incidence of post-transplant diabetes mellitus and its effects on the kidney allograft function and morphology were assessed. Patients were divided into three groups according to their glucose metabolism. Risk factors for diabetes were fi rst assessed, and then changes in renal function were checked. Morphological changes in the allografts were examined by protocol biopsies. The overall incidence of diabetes was 16%. The development of diabetes was infl uenced signifi cantly by the body mass index, the body weight and the age of the recipient. The incidence of diabetes was 8.6% in patients on cyclosporine A therapy and 28.8% in those on tacrolimus ( p < 0.05). As to the morphology of the kidney, a signifi cantly higher proportion of the biopsies showed severe interstitial fi brosis/tubular atrophy ( p = 0.0004) and subclinical acute rejection ( p = 0.001) in the diabetic group compared to the normal one. This clinical study has revealed that the adverse effect of diabetes on the allograft can be detected with protocol biopsy before the manifestation of a functional deterioration.
After kidney transplantation, almost 40% of overall mortality can be attributed to cardiovascular diseases. Diabetes mellitus following transplantation (Tx) is called posttransplant diabetes mellitus (PTDM). According to the criteria of the American Diabetes Association (ADA), diabetes is present if the fasting blood glucose level is ≥ 7 mmol/L, or if the blood glucose level measured 2-h following the oral administration of 75 g glucose (Oral glucose tolerance test, OGTT) is ≥ 11.1 mmol/L. Impaired fasting glucose (IFG) is defi ned as a fasting blood glucose level of between 5.6 mmol/L and 6.9 mmol/L, whereas the normal value (N) for fasting blood glucose is < 5.6 mmol/L or impaired glucose tolerance (IGT) (2-h values in the OGTT) between 7.8 mmol/L and 11.0 mmol/L. PTDM is often not diagnosed, and diabetes without timely treatment is a high risk factor for cardiovascular diseases, graft function deterioration and death (3, 5, 6, 9, 13) . PTDM and diabetes diagnosed before transplantation are equivalent risk factors for cardiovascular diseases. The ethiopathogenesis of PTDM is complex. Endogenous factors, such as the body mass index (BMI), a positive family history, older age, hepatitis C and immunosuppressive (IS) therapy can all play a role in its development (15) . The use of IS drugs, such as steroids (S), cyclosporine A (CsA) or tacrolimus (Tac), is a risk factor for the development of PTDM with an incidence ranging from 2 to 53% among renal transplant recipients (10, 3) . PTDM is caused by insuffi cient Post-transplant diabetes mellitus insulin release in response to an increase in insulin resistance. Since calcineurin inhibitors (CNI) are commonly used with steroid, it is diffi cult to identify whether diabetes in posttransplant setting is due to steroid, CNI or both (10) . Long-term allograft failure because of interstitial fi brosis/tubular atrophy (IF/TA) with defi ned or undefi ned cause (11) is one of the most important reasons for kidney graft loss together with premature patient death with a functioning graft. However, the impact of post-transplant diabetes, or other glucose metabolism abnormalities developing after transplantation, on the progression of histopathological changes attributable to IF/TA in serial protocol biopsies during the fi rst year after transplantation have not been described in detail.
The aim of our study was to assess the incidence of diabetes in kidney transplant patients. Diabetes is known to damage the graft; however, it is uncertain whether this damage is manifested fi rst in a decreased renal function or in a morphological change.
Patients and Methods
Between January 1, 2004, and December 31, 2008, 243 kidney transplantations were performed at the Department of Surgery, University of Szeged, Hungary. We enrolled patients who were alive, receiving treatment and were above the age of 18 years in 2009, and who had received a primary cadaver kidney transplant. Subjects who were under 18 years of age, had a live donor transplant, had known diabetes mellitus prior to transplantation, had already died by the year 2009 or underwent graftectomy were excluded from the study. Thus, 154 patients were included in the study.
Fasting blood glucose level of patients was measured one year after the transplantation. Based on ADA criteria, patients were divided into the following groups: PTDM, IFG, IGT and N. OGTT was performed in each patient. Patients with blood glucose level ≥ 11 mmol/L were selected into the PTDM group. Each patient had ≥ 11 mmol/L 2-hour postload blood glucose level in this group. Patients with normal glucose metabolism formed the control group. In 2008, the measurement of glycated hemoglobin (HbA 1C ) was introduced. In diabetes mellitus, the measurement of HbA 1C serves for the 2-3-month retrospective monitoring of carbohydrate metabolism.
Of the immunosuppressants employed, we studied the effects of the CNI, CsA and Tac on the glucose metabolism. We also examined whether steroids, besides calcineurin inhibitors, have an infl uence on the development of PTDM.
A total of 137 patients received CNI-based immunosuppression. Seventy patients were taking CsA and 22 of them also received a steroid. Tac was given to 67 patients, and 19 of them were taking a steroid as well. Seventeen patients were treated with CNI-free immunosuppressive therapy (Table I) . This complex binds with calcineurin, the normal function of which is to act as a phosphatase that dephosphorylates certain nuclear regulatory proteins and hence facilitates their passage through the nuclear membrane. Inhibition of calcineurin thereby impairs the expression of several critical cytokine genes that promote T-cell activation including those for IL-2, IL-4, interferon-γ, and tumor necrosis factor-α. The transcription of other genes, such as CD40 ligand and the proto-oncogenes is also impaired.
Mechanism of action of the steroid
Steroid exerts two principal effects on the recipient immune system. First, within 4 to 8 hours of administration, they alter the circulation of lymphocytes causing them to be sequestered in the reticuloendothelial system. Second, steroids inhibit the function of lymphocytes by interfering with soluble signals that are important for the recruitment of several types of immune cells to the rejection process (i.e. lymphokines and cytokines) (20) .
Functional and morphological examination of the allograft
Changes in renal function were assessed by the serum creatinine level and the estimated glomerular fi ltration rate (eGFR) in the different glucose metabolism groups. eGFR was calculated using the Cockroft-Gault (CG) and the Modifi cation of diet in renal disease (MDRD) formulas. Before the transplantation, a histological sample was taken from each kidney not yet implanted ("zero hour" biopsy). We studied the one-year protocol biopsies of those patients who had a normal histology result of the zero biopsy. The histology specimens of 115 patients were evaluated. Seven patients disagreed to have biopsy and 32 patients were excluded from the study as the histological result of their zero-hour biopsy showed hypertensive renal disease.
These biopsies were performed under ultrasound guidance with the prior consent of the patients. 16-G Tru-Cut needles and a biopsy gun were used to obtain tissue cylinders. Morphological examinations included standard light microscopic stainings hematoxylineosin PAS, trichrome and methenamine silver), and immunofl uorescence analysis of the frozen sections with antibodies to HLA class II antigens, complement 4d (C4d), C3, IgG, IgA and IgM. Embedding for electron microscopy was carried out in all cases, and ultrastructural evaluation was performed optionally. Renal lesions were graded and diagnosed according to the 2003 modifi cation of the Banff '97 classifi cation. The histological changes were acute rejection (AR), calcineurin inhibitor toxicity (CNI-tox), IF/TA (21) -where IF/TA involved patients with grades II and III, whereas grade I was considered normal -pyelonephritis and others (acute tubular necrosis, glomerulonephritis, and BK polyomavirus nephritis).
Our study was approved by the Regional Human Biomedical Research Ethics Committee of the Albert Szent-Györgyi Clinical Center, University of Szeged (Reg. No.: 17/2009). Each patient was provided with comprehensive information regarding the study.
Post-transplant diabetes mellitus

Immunosuppression
Immunosuppressive drugs administered 1 year after transplantation
Tac is a macrolid molecule that has strong lipophilicity. The initial daily dose of Tac was 0.20 mg/kg in two portions, and then the target blood trough level was 10-15 ng/mL for 6 weeks, and 5-10 ng/mL after week 6. CsA is a lipophilic, hydrophobic, cyclic peptide composed of 11 amino acids.The initial dose of CsA was 8-10 mg/kg daily, in two portions, and then the target blood level was 1,300-1,600 ng/mL in month 1,900-1,300 ng/mL in months 2 and 3, 750-950 ng/mL in months 4 to 6, and 700 ng/mL afterwards (blood levels were determined two hours after administration). Sirolimus (SRL) is a macrolid molecule with a structure similar to that of tacrolimus. The initial dose of sirolimus was 0.1 mg/kg once daily; the target blood trough level was 10-15 ng/mL for 6 weeks and then 5-10 ng/mL. In the case of everolimus (EVR), the initial dose was 0.02 mg/kg twice daily, and then the target trough level was 3-8 ng/mL. A 500 mg steroid was administered intravenously on day 0 in the operating room, immediately before restoring blood fl ow to the graft; 125 mg was administered intravenously on day 1, 32 mg orally on day 2, 24 mg orally on day 3, 16 mg orally on days 4 to 28, 12 mg orally during month 2, 8 mg orally during month 3, and 4 mg orally during months 4 to 6. The dose was further decreased in problem-free cases. The daily dose of mycophenolate mofetil (MMF) was 2 g in two portions and was reduced by 50 or 75% in the event of gastrointestinal symptoms or leucopenia. Antithymocyte globulin (ATG) was administered 1.25 mg/kg for 7 to 21 days. Basiliximab was given on day zero within 2 hours prior to the operation 20 mg i.v. and 20 mg i.v. on day 4.
For the treatment of AR, steroid in a daily dose of 500 mg was administered intravenously for 3 days, followed by 250 mg per day, intravenously for 2 days.
Statistical analysis
For the comparison of mean values, t-test and one-way analysis of variance were used, as well as the Mann-Whitney and Kruskal-Wallis tests in cases of non-normality. The normal distribution of samples was tested by using the Kolmogorov-Smirnov test. Categorical data were analyzed by using chi-square and Fisher's exact test. Temporal changes in renal function parameters were compared by using repeated measures ANOVA. The multivariable dependence of PTDM on both categorical and continuous data was analyzed by means of logistic regression with stepwise (forward) model selection based on the likelihood ratio criterion. SPSS version 15.0 (© 2007 SPSS Inc.) was used for statistical analysis.
Results
After OGTT, 115 patients (75%) were assigned to the control group (having normal glucose metabolism), 8 patients (5%) to the IFG group, 6 patients (4%), to the IGT group and 25 patients (16%) to the PTDM group. Ten of the diabetic patients were receiving treatment: 3 of them were on insulin, whereas 7 were taking oral antidiabetics. Fifteen patients were not given treatment as their abnormal glucose metabolism was identifi ed during the examination. The level of HbA 1C was 4.2 ± 0.2% in the N group, 4.9 ± 0.5% in IFG group, 5.2 ± 0.9% in patients with IGT and 10.4 ± 3.6% in the PTDM group. The difference between the HbA 1C levels was signifi cant ( p < 0.001) when comparing the N and the PTDM groups. Of the initial and post-transplantation data relating to the donor and the recipient, BMI ( p = 0.003), body weight ( p = 0.02) and age of the recipient ( p = 0.005) differed signifi cantly in the control and the PTDM groups (Table II) . As regards the immunosuppressive therapy, the ratio of patients who developed PTDM was 8.6% in those taking CsA, and 26.8% in those on Tac; the difference was signifi cant ( p = 0,004; Table III ). In the case of combined CsA-S treatment, 10.4% of the patients developed diabetes, and there was a signifi cant difference if we compared this to the group of patients taking CsA without steroids 4.5% ( p = 0.044). The incidence of newly developed diabetes among patients on the Tac-S combination was 27.7%; compared to the incidence rate in patients receiving steroid-free immunosuppression 21.1%, which was not signifi cantly different ( p = 0.846). No signifi cant difference, in regard to the development of diabetes, was found between the normal and the PTDM groups in case of the combinations of MMF and Tac ( p = 0.76), SRL and Tac ( p = 0.53), and EVR and Tac ( p = 0.43). Table II , respectively. No signifi cant difference was found between the N and the PTDM groups when comparing the eGFR values (p = 0.34 with the CG and p = 0.46 with the MDRD formula). The post-Tx serum creatinine and eGFR levels in the groups with a different glucose metabolism status were compared by using the repeated measures ANOVA statistical analysis. Regarding the morphological changes of the kidney, there was a signifi cant difference between the PTDM and the N groups in the frequency of severe IF/TA ( p = 0.0004) and subclinical acute rejection ( p = 0.001), whereas no signifi cant difference could be demonstrated in morphological signs of CNI toxicity ( p = 0.075) between the two groups (Table IV, Fig. 1 ). According to the results of a stepwise logistic regression analysis of the data on recipients (gender, age, serum creatinine, urine production in the last 24 hours) and donors (age, gender, serum creatinine, eGFR, BMI, body weight and IS), calcineurin inhibitors had the major effect on the morphological changes of the kidneys. Diabetes mellitus markedly increased the risk of AR and IF/TA (AR: p = 0.025, OR = 7.2, CI = 1.276-40.960; IF/TA: p = 0.0004, OR = 24.9, CI = 4.5-138.219). 
Discussion
The incidence of PTDM was 16% in our patient population. In the studies by Valderhang et al. (28) the incidence of diabetes has been 17% and 14%, respectively. Kamar et al. (12) and Schiel et al. (22) have found similar results, namely that the risk factors of PTDM include not only the immunosuppressive agents, but also family history and age, body weight and BMI of the recipient, and these are at least as important in the development of diabetes (18, 19, 24, 29, 30) . Our clinical study revealed that both IS agents and age, and body weight and BMI of the recipient infl uenced the development of diabetes. In regard to immunosuppressive therapy, we found a signifi cant difference between the effects of Tac and CsA on glucose metabolism (26.8% vs. 8.6%) (29, 30, 31). In a study by Vincenti et al., the incidence of diabetes has been 33.6% with Tac and 26% with CsA treatment (31), whereas Heisel et al. report that the incidence of PTDM has been 16.5% in case of Tac and 9.8% in case of CsA (10) . The difference is signifi cant in both studies. We found a signifi cant difference between combined CsA-S treatment and S-free CsA treatment in regard to the development of diabetes, whereas the difference was not signifi cant between combined Tac-S treatment and S-free Tac treatment (9) . Greater steroid exposure was associated with the development of glucose metabolism abnormalities in the CsA-group but not among tacrolimus-treated patients. This suggests that steroid played a major role in the development of diabetes occurring in the CsA-treated patients. Steroids are diabetogenic and cause insulin resistance. The long-term use of steroids in organ transplant recipients can lead to post-transplantation diabetes, so reduced steroids and steroid-free drug regimens have been instituted at many transplant centers. Calcineurin inhibitors have also been associated with post-transplantation diabetes. Steroids produce increased insulin resistance, whereas calcineurin inhibitors primarily decrease insulin secretion. Cyclosporine A appears to be less diabetogenic than tacrolimus, but both agents may have a direct impact on the transcriptional regulation of insulin gene expression in the pancreatic β cells. The exact mechanism of calcineurin inhibitor induced toxicity to β cell is unknown. The diabetogenic effect of tacrolimus may be reversible, as evidenced by observations that impaired insulin secretion was reversed 3 days after tacrolimus discontinuation and that insulin secretion improved after the reduction of tacrolimus through blood concentration. With the above understanding, in the following Post-transplant diabetes mellitus sections, genes related to diabetes or to the mechanism of developing diabetes are compared with the genes associated with calcineurin inhibitor induced diabetes (7) . When examining the different immunosuppressive combinations, we did not fi nd MMF and SRL to have a diabetogenic effect (3). One year after transplantation, no signifi cant difference could be shown between diabetic patients and normal patients in regard to their serum creatinine and GFR levels (9) . Regarding the morphology of the kidneys, we observed different results in the one-year protocol biopsies. There were signifi cantly more frequent interstitial fi brosis/ tubular atrophy and acute rejection in the diabetic group than in the normal group, whereas the two groups did not differ in regard to CNI-tox (4, 11, 17, 21, 22) . In the study by Arif et al., diabetic and normal patients have differed signifi cantly in IF/TA ( p < 0.001) (2) . This confi rms that the disruption of the glucose homeostasis severely damages the allograft, which is fi rst manifested in the morphology, followed by a decrease in renal function. One year after kidney transplantation diabetic nephropathy (especially mesangial matrix increase and arteriola hyalinosis) does not develop, however, permanent hyperglycemia may result in morphological changes of the allograft. In IF/TA, hyperglycemia may lead to fi brogenesis by decreasing the number of functioning nephrons. One year after normal "zero-hour" biopsy diabetes may damage the allograft, however, no deterioration in function can be detected. Histological changes can be identifi ed by protocol biopsy in time, and accordingly diabetic nephropathy and end stage renal failure can be prevented. One year after transplantation, differences in the functional and morphological state of the allograft were presumed to be due to the phenomenon that the kidney tries to compensate for the loss of functioning kidney tissues with the overburdening, hypertrophy and hyperfi ltration of the intact glomeruli. Therefore, the allograft shows morphological changes but no functional ones. The cardiovascular risk of kidney transplant patients may be decreased, and the long-term survival of the graft may be increased by the timely recognition and treatment of diabetes (1, 3) . It is important to check glucose metabolism regularly by measuring the fasting blood glucose level and the level of HbA 1C every three months. Later, in case of a worsening glucose metabolism, a reduction in the dose of the calcineurin inhibitor and even a switch to a calcineurin inhibitor-free combination may be considered. Thus, with the timely initiation of treatment, the graft may be preserved in the long term, and the risks of diabetes may be decreased. By means of the protocol biopsy, an individually tailored immunosuppressive therapy can be set up for each patient, which may not only promote allograft function, but might also increase the survival of the patient.
